Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Annlicat	tion Data S	shoot 37	CED 1 76	Attorne	ey Docket	Numbe	er 7010	)49				
Аррпса	lion Data S	oneet or	CI K 1.70	Applica	ation Num	ber						
Title of Inv	rention SC	REENING M	METHOD FOR	R SOMATIO	C CELL NU	CLEAR	REPROG	SRAM	MING SUE	BSTANC	E	
bibliographic This docume	on data sheet is data arranged ir ent may be com ay be printed and	n a format spe pleted electro	ecified by the U nically and sul	nited States bmitted to th	Patent and	Tradema	rk Office as	outlin	ed in 37 CF	R 1.76.		
Secrecy	Order 3	7 CFR 5	5.2									
	ns or all of the R 5.2 (Pape											suant to
Applica	nt Inform	ation:										
Applicant	:1									Remov	е	
	Authority •	Inventor	OLegal Re	presentativ	ve under 3	5 U.S.C.	. 117	ОР	arty of Inte	rest und	er 35 U.S	.C. 118
	iven Name	<u>'</u>	N	liddle Na	me		Fam	nily N	y Name			Suffix
Sh	ninya						YAN	IANAI	KA			
Residenc	e Informatio	n (Select (	One) 🔘 U	S Residenc	су 💿	Non US	Residenc	у (	) Active I	JS Milita	ıry Servic	e
City Os	aka-shi		Cour	ntry Of Re	esidencei	JP						
Citizensh	ip under 37 (	CFR 1.41(b	<b>))</b> i JP									
Mailing A	ddress of Ap	plicant:	•									
Address '	1	2-9-7-140	1, Dougashik	ра								
Address 2	2	Tennoji-k	u									
City	Osaka-shi, C	)saka			St	ate/Pro	ovince					
Postal Co	de	543-0033			Country	/i JP						
	ors Must Be within this fo				Informatio	n block	ks may	be		Add		
Corresp	ondence	Inform	ation:									
	er Customer er informatio				responde	nce Inf	ormation	n sec	tion belo	w.		
☐ An A	ddress is be	ing provid	led for the o	correspor	ndence In	format	ion of th	is ap	plication	-		
Customer	Number	23460										
Email Address email@leydig.co			@leydig.com	Add Email			ail	Remove	Email			
Applica	tion Infor	mation	:									
Title of the Invention SCREENING METHOD FOR SOMATIC CELL NUCLEAR REPROGRAMMING SUBS					IBSTANC	E						
Attorney Docket Number 701049						Small	Entity St	atus	Claimed			
Application	on Type	Nonpr	Nonprovisional									
Subject M	latter	Utility										
Suggeste	d Class (if a	ıy)	Sub Class (if any)									
Suggeste	d Technolog	y Center (	if any)				•					
	her of Draw	- '		9		Sunne	sted Fin	ııra f	or Public	ation (i	if any)	1

Approved for use through 06/30/2010. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

onder the raperito	in readoubli rioi di 1000, no per	sons are required to respond to a concon		JO IL CONTUNIN	d talla	OIVID OUT	OI HUIHDE	
Application Data Sheet 37 CFR 1.		Attorney Docket Number	701049					
Application Data Si	neet 37 CFR 1.76	Application Number						
Title of Invention SCR	REENING METHOD FOR	R SOMATIC CELL NUCLEAR REPROGRAMMING SUBSTANCE						
Publication Info	rmation:							
Request Early Publ	ication (Fee required a	time of Request 37 CFR 1.2	?19)					
C. 122(b) and certif	y that the invention dis in another country, or u	eby request that the attached closed in the attached applic inder a multilateral internation	ation has not a	nd will r	not be	the su	ıbject of	
	n should be provided fo	r all practitioners having a po					roviding	
Enter either Customer	Number or compl	ot constitute a power of attorney ete the Representative N r the Representative Information	lame section	below.	CFR f	•	sections	
Please Select One:	Customer Number	US Patent Practitione	er Cimited	Limited Recognition (37 CFR 11.9)				
Customer Number	23460							
Domestic Benefit/National Stage Information:  This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage								
		ion in the application data sheet FR 1.78(a)(4), and need not oth						
Prior Application Statu	ıs			Re	move			
Application Number	Continuity <sup>1</sup>	Type Prior Applicati	on Number I	Filing Date (YYYY-MM-DD		M-DD)		
10589905	a 371 of internationa	PCT/JP2005/00:	2842 20	2005-02-16				
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the <b>Add</b> button.								
Foreign Priority I	nformation:							
		of foreign priority and to identify tion data sheet constitutes the c		required				
Application Number	Country	/ i Parent Filing D	ate (YYYY-MM-			iority C	laimed	
2004-042337	JP	2004-02-19	•		<u> </u>	Yes (		
				Re	move	- \		
Application Number	Country	y i Parent Filing D	ent Filing Date (YYYY-MM-DD) Priority Cl			laimed		
2004-232961	JP	2004-08-10			• '	Yes (	) No	
				Re	move			
Application Number	Country	y i Parent Filing D	ate (YYYY-MM-	-DD)	Pr	iority C	laimed	
2004-276572	JP	2004-09-24			• '	Yes (	) No	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ta Sheet 37 CFR 1.76	Attorney Docket Number	701049		
Application Da	ta Sileet 37 CFK 1.70	Application Number			
Title of Invention	SCREENING METHOD FOR	PROGRAMMING SUBSTANCE			

Additional Foreign Priority Data may be generated within this form by selecting the Add button.

Add button.

## **Assignee Information:**

Providing this information of the CFR to have an as			substitute for compliance w	ith any requirement of part 3 of Title 37				
Assignee 1				Remove				
If the Assignee is an O	rganization check	here.						
Organization Name	Kyoto University							
Mailing Address Info	rmation:							
Address 1 36-1, Yoshida-honmachi								
Address 2	Sakyo-ku	Sakyo-ku						
City	Kyoto-shi, Ky	oto	State/Province					
Country i JP			Postal Code	606-8501				
Phone Number			Fax Number					
Email Address			•					
Assignee 2	·			Remove				
If the Assignee is an O	rganization check	here.						
Organization Name	Dainippon Sumito	omo Pharma Co., Lto	d.					
Mailing Address Info	Mailing Address Information:							
Address 1	6-8, Dosho-n	6-8, Dosho-machi 2-chome						
Address 2	Chuo-ku	Chuo-ku						
City	Osaka-shi, O	saka	State/Province					
Country i JP	-		Postal Code	541-8524				
Phone Number			Fax Number					
Email Address				<u>'</u>				
Additional Assignee D button.	ata may be gene	rated within this fo	orm by selecting the Ad	d Add				

## Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.							
Signature	/John Kilyk, Jr./		Date (YYYY-MM-DD) 2008-10-30				
First Name	John	Last Name	Kilyk, Jr.	Registration Number	30763		

PTO/SB/14 (07-07) Approved for use through 06/30/2010. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application Data Sheet 37 CFR 1.76

Attorney Docket Number 701049

Application Number SCREENING METHOD FOR SOMATIC CELL NUCLEAR REPROGRAMMING SUBSTANCE

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.